XML 67 R34.htm IDEA: XBRL DOCUMENT
v3.23.3

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Details) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | ---
Sep. 30, 2019 USD ($) performance_obligation material_right | Apr. 30, 2018 USD ($) option milestone | Sep. 30, 2023 USD ($) $ / shares | Sep. 30, 2023 USD ($) $ / shares | Dec. 31, 2022 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Accounts receivable |  |  | $ 1,148 | $ 1,148 | $ 3,678
Kite Pharma, Inc. | Change In Agreement Estimate, March 2023 |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Increase in revenue |  |  |  | 8,900 |
Decrease in net loss |  |  |  | $ 8,900 |
Increased earnings per share, basic (in dollars per share) | $ / shares |  |  |  | $ (0.05) |
Increased earnings per share, diluted (in dollars per share) | $ / shares |  |  |  | $ (0.05) |
Kite Pharma, Inc. | Change In Estimate, September 2023 |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Increase in revenue |  |  | 4,900 | $ 4,900 |
Decrease in net loss |  |  | $ 4,900 | $ 4,900 |
Increased earnings per share, basic (in dollars per share) | $ / shares |  |  | $ (0.03) | $ (0.03) |
Increased earnings per share, diluted (in dollars per share) | $ / shares |  |  | $ (0.03) | $ (0.03) |
Kite Pharma, Inc. | License and Service |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Remaining performance obligation amount, related to material rights |  |  | $ 1,500 | $ 1,500 | 1,500
Kite Pharma, Inc. | License and Service | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Remaining performance obligation amount |  |  |  |  | $ 21,200
Remaining performance obligation, expected timing of satisfaction period |  |  |  |  | 12 months
Kite Pharma, Inc. | License and Service | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01 |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Remaining performance obligation amount |  |  | $ 1,500 | $ 1,500 |
Remaining performance obligation, expected timing of satisfaction period |  |  | 12 months | 12 months |
Kite Pharma, Inc. | License |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Contract with customer liability |  | $ 150,000 |  |  |
Number of remaining performance obligations | performance_obligation | 4 |  |  |  |
Number of material rights for renewal of research period | material_right | 2 |  |  |  |
Renewal period | 1 year |  |  |  |
Fixed consideration | $ 150,000 |  |  |  |
Kite Pharma, Inc. | Collaboration And License Agreement |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Milestone payments received |  | $ 150,000 |  |  |
Initial research term of agreement |  | 6 years |  |  |
Number of options to extend initial research term | option |  | 2 |  |  |
Extended research term of agreement |  | 1 year |  |  |
Separate fee for additional term |  | $ 10,000 |  |  |
Contract with customer liability |  |  | $ 1,500 | $ 1,500 | $ 19,400
Accounts receivable |  |  | $ 200 | $ 200 | $ 700
Kite Pharma, Inc. | Collaboration And License Agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Contingent development and sales-based milestone payments to be received |  | 1,300,000 |  |  |
Kite Pharma, Inc. | Collaboration And License Agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Contingent development and sales-based milestone payments to be received |  | $ 1,800,000 |  |  |
Maximum amount of achieved milestones to receive payment | milestone |  | 10 |  |  |
Kite Pharma, Inc. | Collaboration And License Agreement | Maximum |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Development and sales-based milestone payments to be received |  | $ 3,000,000 |  |  |

X
- Definition Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Be Eligible For Payment + References No definition available. + Details
Name: | sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent development and sales based milestone payments to be received. + References No definition available. + Details
Name: | sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Customer contract liability milestone payment eligible to receive. + References No definition available. + Details
Name: | sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Extended Research Term Of Agreement + References No definition available. + Details
Name: | sgmo_ExtendedResearchTermOfAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase (Decrease) In Earnings Per Share, Basic + References No definition available. + Details
Name: | sgmo_IncreaseDecreaseInEarningsPerShareBasic
Namespace Prefix: | sgmo_
Data Type: | dtr-types1:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase (Decrease) In Earnings Per Share, Diluted + References No definition available. + Details
Name: | sgmo_IncreaseDecreaseInEarningsPerShareDiluted
Namespace Prefix: | sgmo_
Data Type: | dtr-types1:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase (Decrease) In Net Income (Loss) Attributable To Parent + References No definition available. + Details
Name: | sgmo_IncreaseDecreaseInNetIncomeLossAttributableToParent
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase (Decrease) In Revenue From Contract With Customer, Excluding Assessed Tax + References No definition available. + Details
Name: | sgmo_IncreaseDecreaseInRevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Initial research term of agreement. + References No definition available. + Details
Name: | sgmo_InitialResearchTermOfAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payments received. + References No definition available. + Details
Name: | sgmo_MilestonePaymentsReceived
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number Of Options To Extend Initial Research Term + References No definition available. + Details
Name: | sgmo_NumberOfOptionsToExtendInitialResearchTerm
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Number Of Remaining Performance Obligations + References No definition available. + Details
Name: | sgmo_RevenueNumberOfRemainingPerformanceObligations
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenue, Remaining Performance Obligation, Fixed Consideration Amount + References No definition available. + Details
Name: | sgmo_RevenueRemainingPerformanceObligationFixedConsiderationAmount
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue, Remaining Performance Obligation, Number Of Material Rights For Renewal Of Research Period + References No definition available. + Details
Name: | sgmo_RevenueRemainingPerformanceObligationNumberOfMaterialRightsForRenewalOfResearchPeriod
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenue, Remaining Performance Obligation, Related To Material Rights, Amount + References No definition available. + Details
Name: | sgmo_RevenueRemainingPerformanceObligationRelatedToMaterialRightsAmount
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue, Remaining Performance Obligation, Renewal Period + References No definition available. + Details
Name: | sgmo_RevenueRemainingPerformanceObligationRenewalPeriod
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Separate upfront fee. + References No definition available. + Details
Name: | sgmo_SeparateUpfrontFee
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInAgreementEstimateMarch2023Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInAgreementEstimateSeptember2023Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-10-01
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |